Journal
CNS drugs
Publication Date
2-1-2020
Volume
34
Issue
2
First Page
185
Last Page
196
Document Type
Open Access Publication
DOI
10.1007/s40263-020-00700-0
Rights and Permissions
Naismith, R.T., Wundes, A., Ziemssen, T. et al. Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study. CNS Drugs 34, 185–196 (2020). https://doi.org/10.1007/s40263-020-00700-0 This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Recommended Citation
Naismith, Robert T and et al., "Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: Results from the randomized, double-blind, phase III EVOLVE-MS-2 study." CNS drugs. 34, 2. 185 - 196. (2020).
https://digitalcommons.wustl.edu/oa_4/440
Supplementary Material
